LONDON — Novo Nordisk’s diabetes remedy Ozempic minimize the chance of sufferers growing superior kidney illness or dying from kidney or coronary heart problems, the corporate stated Tuesday, including to the proof the wildly common drug has broader well being advantages for sufferers past addressing their diabetes.
Total, Ozempic lowered the chance of development of sufferers’ kidney illness and of associated well being occasions by 24% versus placebo, in line with the topline outcomes. The corporate, which can current full information from the examine later this yr, stated it might file for an expanded approval of Ozempic based mostly on the information in each the U.S. and Europe.
The constructive announcement had been anticipated since October, when Novo introduced it was ending the FLOW trial early as a result of an interim information evaluation confirmed the drug was surpassing the examine’s objectives. Nonetheless, the outcomes present an necessary information level for Novo each as its medicines face growing competitors and because it tries to get extra insurers to cowl its associated weight problems drug Wegovy.